Sonoma Pharmaceuticals, Inc.
SNOA
$1.10
-$0.03-2.66%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 19.53M | 17.72M | 16.94M | 14.91M | 14.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.53M | 17.72M | 16.94M | 14.91M | 14.29M |
| Cost of Revenue | 12.11M | 10.96M | 10.56M | 9.29M | 8.82M |
| Gross Profit | 7.42M | 6.76M | 6.38M | 5.62M | 5.47M |
| SG&A Expenses | 7.61M | 7.39M | 7.49M | 7.32M | 7.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.99M | 20.49M | 20.06M | 18.54M | 18.00M |
| Operating Income | -2.46M | -2.77M | -3.12M | -3.63M | -3.71M |
| Income Before Tax | -3.42M | -3.45M | -3.42M | -3.15M | -2.91M |
| Income Tax Expenses | -244.00K | -80.00K | 59.00K | 403.00K | 550.00K |
| Earnings from Continuing Operations | -3.18 | -3.37 | -3.48 | -3.56 | -3.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.18M | -3.37M | -3.48M | -3.56M | -3.46M |
| EBIT | -2.46M | -2.77M | -3.12M | -3.63M | -3.71M |
| EBITDA | -2.32M | -2.63M | -2.98M | -3.50M | -3.57M |
| EPS Basic | -1.89 | -2.04 | -2.20 | -2.46 | -3.05 |
| Normalized Basic EPS | -1.28 | -1.30 | -1.35 | -1.35 | -1.61 |
| EPS Diluted | -1.89 | -2.04 | -2.20 | -2.46 | -3.05 |
| Normalized Diluted EPS | -1.28 | -1.30 | -1.35 | -1.35 | -1.61 |
| Average Basic Shares Outstanding | 6.74M | 6.61M | 6.36M | 5.75M | 4.96M |
| Average Diluted Shares Outstanding | 6.74M | 6.61M | 6.36M | 5.75M | 4.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |